000			03809nam a22003615i 4500
001			76167
003			ES-MaUEC
005			20230207040212.0
007			cr nn 008mamaa
008			100301s2006 xxu| s |||| 0|eng d
020			_a9781592599622
024	7		_a10.1385/1592599621 _2doi
050		4	_aRC271.P76 _bF333 2006 EB
082	0	4	_a572
100	1		_aFabbro, Doriano _eeditor literario _0Local _985082
245	1	0	_aProtein Tyrosine Kinases : _bFrom Inhibitors to Useful Drugs _cedited by Doriano Fabbro, Frank McCormick.
260			_aTotowa, NJ _bHumana Press _c2006
300			_a1 recurso en línea (XIII, 290 páginas)
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aCancer Drug Discovery and Development
505	0		_aProtein Tyrosine Kinases as Targets for Cancer and Other Indications -- Inhibitors of Signaling Interfaces -- PI3-Kinase Inhibition -- Src as a Target for Pharmaceutical Intervention -- Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia -- JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma -- Glivec® (Gleevec®, Imatinib, STI571) -- Platelet-Derived Growth Factor -- Structural Biology of Protein Tyrosine Kinases -- Testing of Signal Transduction Inhibitors in Animal Models of Cancer -- Phosphoproteomics in Drug Discovery and Development.
520			_aProtein kinases function as components of signal transduction pathways, playing a central role in the control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein tyrosine kinase (PTK) inhibitors that can block or modulate diseases, such as cancer, with abnormalities in these signaling pathways is considered a promising approach for drug development. Currently, more than 20 different PTKs are being considered as potential therapeutic targets in oncology. In Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, leading researchers from the Novartis group that pioneered Gleevec/Glivecâ{u2821}nd from around the world comprehensively survey the state-of-the-art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made toward generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing PTK inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors. Authoritative and state-of-the-art, Protein Tyrosine Kinases: From Inhibitors to Useful Drugs details the key stages in the design of PTK inhibitors and their development into useful drugs.
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisando
650		7	_aBioquímica _0LocalV _2embne _9138639
700	1		_aMcCormick, Frank _eeditor literario _985083 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1385/1592599621 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12817855 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gxxu _h0
945			_aRC271.P76 F333 2006 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11547078 _z06-04-17
999			_c76167 _d76167 _x1